Indications and uses
relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages
relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages
adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) do not chew tablet children under 12 years: ask a doctor
| Active ingredient (in each tablet) | Purpose |
| Ranitidine 75 mg (as ranitidine hydrochloride 84 mg) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . | Acid reducer |
Allergy alert: Do not use if you are allergic to ranitidine or other acid reducers
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
hypromellose, magnesium stearate, microcrystalline cellulose, iron oxide, titanium dioxide, triacetin
call 1-888-285-9159 (English/Spanish) M – F, 8:30 – 5 EST, or visit www.zantacotc.com
Read the directions, consumer information leaflet and warnings before use. Keep the carton. It contains important information.
Distributed by: Boehringer Ingelheim (BI) Consumer Health Care Products
Division of BI Pharmaceuticals, Inc., Ridgefield, CT 06877
© 2016, BI Pharmaceuticals, Inc. All rights reserved.
Product of Spain. Manufactured in Mexico.
Product: 68151-2584
NDC: 68151-2584-0 1 TABLET, COATED in a PACKAGE
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 312773 | ranitidine 75 MG Oral Tablet | PSN | 5 |
| 827183 | Zantac 75 MG Oral Tablet | PSN | 5 |
| 827183 | ranitidine 75 MG Oral Tablet [Zantac] | SBD | 5 |
| 312773 | ranitidine 75 MG Oral Tablet | SCD | 5 |
| 312773 | ranitidine 75 MG (as ranitidine hydrochloride 84 MG) Oral Tablet | SY | 5 |
| 827183 | Zantac 75 75 MG Oral Tablet | SY | 5 |
| 827183 | Zantac 75 MG (as ranitidine hydrochloride 84 MG) Oral Tablet | SY | 5 |
| Class | Version | Type | Effective |
|---|---|---|---|
| RANITIDINE Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 7f54af34-be54-4c3c-894f-78df6452d747 | Product name | 3 | 20190703 |
| ccf8541e-b7dc-e6ba-06c9-15bf143a7850 | Product name | 5 | 20190611 |
| 05700d9e-ea6f-4aab-b0ed-1488f1d85d7b | Product name | 1 | 20180904 |
| 2f9d4e5c-e179-490e-8c43-f19e1e0ca228 | Product name | 1 | 20160720 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68151-2584-0 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-42c1-f424-e053-dadaa90a57ce | Zantac 75 ® Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68151-2584-0 | Zantac 75 | 1 in 1 PACKAGE | TABLET, COATED | 1 | 5 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68151-2584 | ZANTAC 75 (RANITIDINE) TABLET, COATED [CARILION MATERIALS MANAGEMENT] | 5 | Legacy NDC, 1 package rows | 20171228_6b52d3b3-aca0-450e-985c-0a062d4ab5c2.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0597-0122-13 | EA - Each | 0597-0122 | 5a13a602-c54e-42c4-9cef-24838673b0bf | 1 | 2019-01-24 |
| 0597-0122-27 | EA - Each | 0597-0122 | afb7291f-7243-4c18-bdee-e0879aa0c616 | 1 | 2012-07-24 |
| 0597-0122-37 | EA - Each | 0597-0122 | ee19f11b-ad30-42d0-891e-1107a171b390 | 1 | 2012-07-24 |
| 0597-0122-54 | EA - Each | 0597-0122 | ed679226-297f-44f2-bdb7-4858939d94af | 1 | 2012-07-24 |
| 0597-0122-81 | EA - Each | 0597-0122 | 3cff1c2d-45e2-42a7-9fba-d96088f38dcb | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ranitidine hydrochloride | ACTIVE INGREDIENT | BK76465IHM | 2 | |
| ranitidine | ACTIVE MOIETY | 884KT10YB7 | 2 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 2 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 2 | |
| HYPROMELLOSES | INACTIVE INGREDIENT | 3NXW29V3WO | 2 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| TRIACETIN | INACTIVE INGREDIENT | XHX3C3X673 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68151-2584 | 68151-2584-0 |
| 0597-0122 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| RANITIDINE HYDROCHLORIDE | BK76465IHM | ACTIM |
| HYPROMELLOSE, UNSPECIFIED | 3NXW29V3WO | IACT |
| magnesium stearate | 70097M6I30 | IACT |
| MICROCRYSTALLINE CELLULOSE | OP1R32D61U | IACT |
| ferric oxide red | 1K09F3G675 | IACT |
| titanium dioxide | 15FIX9V2JP | IACT |
| triacetin | XHX3C3X673 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | SUSPENSION, EXTENDED RELEASE / ORAL | 1120 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | GRANULE, FOR SUSPENSION / ORAL | 143 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | INSERT, EXTENDED RELEASE / OPHTHALMIC | 0.4 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, EXTENDED RELEASE / ORAL | 1472 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | INSERT / VAGINAL | 54.21 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | SYRUP / ORAL | 250 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TROCHE / ORAL | 300 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, EXTENDED RELEASE / ORAL | 67 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, EXTENDED RELEASE / ORAL | 1246 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 1576 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, COATED PELLETS / ORAL | 456 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED / ORAL | 0.12 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, COATED / ORAL | 1 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, EXTENDED RELEASE / ORAL | 5 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / OPHTHALMIC | 0.5 %w/w | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, EXTENDED RELEASE / ORAL | 119.7 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SHAMPOO, SUSPENSION / TOPICAL | 3 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CREAM / TOPICAL | 80 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | TABLET, COATED / ORAL | 1 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUSPENSION / ORAL | 113 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | SUSPENSION, EXTENDED RELEASE / ORAL | 4 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FOR SUSPENSION / ORAL | 20100 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / SUBLINGUAL | 1 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, DELAYED RELEASE / ORAL | 66 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, DELAYED RELEASE / ORAL | 79 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SUSPENSION / ORAL | 4441 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM / BUCCAL | 3 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | TABLET / ORAL | 208 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED PELLETS / ORAL | 2 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY / VAGINAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SYSTEM / TOPICAL | 420 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, ORALLY DISINTEGRATING / ORAL | 2 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION / ORAL | 64 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | POWDER, FOR SUSPENSION / ORAL | 12 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / SUBCUTANEOUS | 0.5 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | LOTION / TOPICAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / ORAL | 305 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | SUSPENSION / ORAL | 7 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N020520-001 | ZANTAC 75 | RANITIDINE HYDROCHLORIDE | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N020520-001 | ZANTAC 75 | EQ 75MG BASE | TABLET / ORAL | RLD | 1995-12-19 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 18b916c5-b24f-4855-96f3-881e43be87c5 | 6b52d3b3-aca0-450e-985c-0a062d4ab5c2 | 2017-12-28 | Warnings | 18b916c5-b24f-4855-96f3-881e43be87c5 6b52d3b3-aca0-450e-985c-0a062d4ab5c2 |
Adverse event summaries are temporarily unavailable. Other product information remains available.